[Retracted] Imatinib inhibits oxidative stress response in spinal cord injury rats by activating Nrf2/HO‑1 signaling pathway

IF 2.4 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Limin Liu, Jingyuan Zhou, Yufeng Wang, Tengmin Qi, Zengshun Wang, Linxu Chen, Nananxiu Suo
{"title":"[Retracted] Imatinib inhibits oxidative stress response in spinal cord injury rats by activating Nrf2/HO‑1 signaling pathway","authors":"Limin Liu, Jingyuan Zhou, Yufeng Wang, Tengmin Qi, Zengshun Wang, Linxu Chen, Nananxiu Suo","doi":"10.3892/etm.2023.12280","DOIUrl":null,"url":null,"abstract":"Following the publication of this paper, the authors personally requested that the article be retracted on account of their subsequent realization that they had used improper experimental methods, combined with general concerns about the published data and the fact that a large number of the experimental findings were found to be irreproducible. Independently of the authors’ request, it was drawn to the Editor’s attention by a concerned reader that the immunohistochemical data shown in the various data panels in Fig. 1 on p. 599 were overlapping, such that data which had been included in the figure to represent different experimental conditions may have been derived from the same original source(s). In addition, control western blotting data shown in Fig. 3 on p. 600 were strikingly similar to data appearing in different form in other articles written by different authors at different research institutes, which had either already been published or were under consideration for publication at around the same time. Owing to the fact that contentious data in the above article had already been published prior to its submission to <em>Experimental and Therapeutic Medicine</em>, and also based on an overall lack of confidence in the presented data, the Editor has accepted the request of the authors to retract this paper from the Journal. The Editor apologizes to the readership for any inconvenience caused. [Experimental and Therapeutic Medicine 19: 597‑602, 2020; DOI: 10.3892/etm.2019.8270]","PeriodicalId":12285,"journal":{"name":"Experimental and therapeutic medicine","volume":"13 1","pages":"0"},"PeriodicalIF":2.4000,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and therapeutic medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3892/etm.2023.12280","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Following the publication of this paper, the authors personally requested that the article be retracted on account of their subsequent realization that they had used improper experimental methods, combined with general concerns about the published data and the fact that a large number of the experimental findings were found to be irreproducible. Independently of the authors’ request, it was drawn to the Editor’s attention by a concerned reader that the immunohistochemical data shown in the various data panels in Fig. 1 on p. 599 were overlapping, such that data which had been included in the figure to represent different experimental conditions may have been derived from the same original source(s). In addition, control western blotting data shown in Fig. 3 on p. 600 were strikingly similar to data appearing in different form in other articles written by different authors at different research institutes, which had either already been published or were under consideration for publication at around the same time. Owing to the fact that contentious data in the above article had already been published prior to its submission to Experimental and Therapeutic Medicine, and also based on an overall lack of confidence in the presented data, the Editor has accepted the request of the authors to retract this paper from the Journal. The Editor apologizes to the readership for any inconvenience caused. [Experimental and Therapeutic Medicine 19: 597‑602, 2020; DOI: 10.3892/etm.2019.8270]
[撤回]伊马替尼通过激活Nrf2/HO‑1信号通路抑制脊髓损伤大鼠氧化应激反应
在这篇论文发表后,作者个人要求撤回这篇文章,因为他们后来意识到他们使用了不恰当的实验方法,再加上对已发表数据的普遍担忧,以及发现大量实验结果是不可复制的。独立于作者的要求,一位关心的读者提请编辑注意,599页图1中各种数据面板中显示的免疫组织化学数据是重叠的,因此图中包含的代表不同实验条件的数据可能来自相同的原始来源。此外,第600页图3所示的对照western blotting数据与不同研究机构的不同作者在大约同一时间已经发表或正在考虑发表的其他文章中以不同形式出现的数据惊人地相似。由于上述文章中有争议的数据在提交给《实验与治疗医学》之前已经发表,并且基于对所呈现数据的总体缺乏信心,编辑已经接受了作者的请求,从该杂志撤回这篇论文。对于由此给读者带来的不便,本刊编辑深表歉意。实验与治疗医学19:597‑602,2020;DOI: 10.3892 / etm.2019.8270]
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Experimental and therapeutic medicine
Experimental and therapeutic medicine MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
1.50
自引率
0.00%
发文量
570
审稿时长
1 months
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信